Mounjaro vs Zepbound: Same Medicine, Different Label
Mounjaro and Zepbound are the same medication, tirzepatide, from the same maker, at the same doses. What differs is the condition each one is approved to treat, how insurance treats them, and what you pay. Here is the difference in plain terms, and which one a provider is likely to reach for.
Medically reviewed by Elara Care Team (Elara editorial, clinical claims reviewed with Wasef Health). Last reviewed September 3, 2026.
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide. | Tirzepatide. The identical molecule, from the same manufacturer. |
| Maker | Eli Lilly. | Eli Lilly. |
| Approved for | Type 2 diabetes, alongside diet and exercise. | Chronic weight management in adults with obesity, or overweight with a weight related condition, and moderate to severe obstructive sleep apnea with obesity. |
| Dosing | Once weekly injection, 2.5 mg titrated up to a maximum of 15 mg. | Once weekly injection, the same 2.5 mg to 15 mg range and the same titration. |
| Used for weight loss | Off label. The medication works the same way, but weight management is not what this label covers. | On label. This is the version approved for it. |
| Price at Elara | $1,750 for one month. | $1,400 for one month. |
| Insurance | More often covered, because diabetes coverage is more established. Elara is cash pay either way. | Coverage for weight management is far less consistent and many plans exclude it. Elara is cash pay either way. |
| Cheaper route to the same molecule | Compounded tirzepatide from $355 for one month. | Compounded tirzepatide from $355 for one month. |
Why one medicine has two names
The FDA approves a medication for a specific use, not in general. Eli Lilly ran tirzepatide through diabetes trials and it was approved as Mounjaro, then ran it through obesity trials and it was approved as Zepbound. Same molecule, same pens, two labels, two prices, and two very different conversations with an insurer.
Which one a provider chooses
If you have type 2 diabetes, Mounjaro is the on label choice. If the goal is weight, Zepbound is, and at Elara it also happens to be the cheaper of the two at $1,400 against $1,750 for a month. Prescribing Mounjaro for weight is off label, which is legal and common but is a decision your provider makes with you rather than a box you tick.
The cheaper route to the same molecule
Both brand versions are expensive. Compounded tirzepatide starts at $355 for one month, or $1,790 for six. It contains the same active ingredient, prepared per prescription for you by a licensed US 503A pharmacy, and it is not reviewed by the FDA for safety or effectiveness the way the brand product is. That trade is the whole decision, and it is set out in compounded vs brand name GLP-1s.
Starting either one
Elara prescribes both after a free online consultation reviewed by a licensed provider, and you are only charged if you are prescribed. Compare the compounded semaglutide plans and the compounded tirzepatide plans, see every price on the pricing page, or start from the weight care overview.
If you are comparing molecules rather than labels, see semaglutide vs tirzepatide. The semaglutide equivalent of this page is Ozempic vs Wegovy.
Frequently asked questions
Is Zepbound just Mounjaro with a different name?
Effectively yes. Both are tirzepatide from Eli Lilly at the same 2.5 mg to 15 mg weekly doses. The difference is the condition each is approved for, which drives insurance coverage and price rather than what the medicine does in your body.
Can I take Mounjaro for weight loss?
A provider can prescribe it off label, and many do. Zepbound is the version approved for weight management, and at Elara it is also the less expensive of the two, so it is usually the more straightforward choice.
Why is Zepbound cheaper than Mounjaro at Elara?
Pricing follows what each product costs to source, not what it does. The two are equivalent medicines, so where the prices differ, the cheaper one is simply the better buy.
Do they have the same side effects?
Yes. Same molecule, same profile: nausea, reduced appetite, constipation or diarrhea are the common ones, mostly early and while the dose is increasing. Both carry the same boxed warning about thyroid C-cell tumors seen in rodent studies.